Where I see patients (1)
My reviews
Selected research
-
Distinguishing between help and harm: Helper T cell subsets and immune-related adverse events.
The Journal of clinical investigation
-
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.
Annals of oncology : official journal of the European Society for Medical Oncology
-
Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response.
BJC reports
Clinical trials
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
The investigators will identify the genes predictive of response to anti-PD-1 therapy by testing for significant associations across expression rates of each gene and response/resistance, within a hurdle-Gaussian mixed-effect fram...
Recruiting
Contact me
- Request appointment
- Refer a patient
- (415) 353-9900
4.9